Results 91 to 100 of about 1,498,034 (139)

Cholesterol-Lowering Treatment Blocks Epithelial-Mesenchymal Transition (EMT) Associated Invasiveness and Drug Resistance in Breast and Colorectal Adenocarcinoma Models. [PDF]

Cancer Med
Perumal S, Abdulla N, Aronson R, Kaur M.
europepmc   +1 more source

Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Adv Ther
Masson W, Lobo M, Giunta G, Barbagelata L, Nogueira JP.   +4 more
europepmc   +1 more source

The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta-Analysis and Trial Sequential Analysis. [PDF]

Cardiovasc Ther
Wang S, Li C, Fan D.
europepmc   +1 more source

Sitosterolemia due to compound heterozygous mutations in ABCG5: a case report. [PDF]

J Med Case Rep
Wu LL, Zhang L, Tang TT, Zhou YY, Chang XX, Guo W, Yan HM, Lin HD.   +7 more
europepmc   +1 more source

Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis. [PDF]

J Atheroscler Thromb
Shimizu Y, Yokouchi-Konishi T, Aoki-Kamiya C, Temukai M, Hizuka K, Sawada M, Kakigano A, Iwanaga N, Kanagawa T, Murai K, Makino H, Yoshimatsu J.   +11 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study. [PDF]

Clin Pharmacol Ther
Nardi Agmon I, Gurevitz C, Shochat T, Kushnir S, Witberg G, Levi A, Gilon D, Kornowski R, Thavendiranathan P, Abdel Qadir H, Iakobishvili Z.   +10 more
europepmc   +1 more source

Choosing the Right Non-Statin Therapy for the Right Patient - How To Sequence Advanced Lipid-Lowering Therapies. [PDF]

Curr Atheroscler Rep
Katzmann JL, Laufs U.
europepmc   +1 more source

Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care? [PDF]

Curr Cardiol Rep
Brandts J, Marx N.
europepmc   +1 more source

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.

JAMA Netw Open
Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE.   +20 more
europepmc   +1 more source

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis. [PDF]

Am J Cardiovasc Drugs
Raone L, Gritti V, Mandurino-Mirizzi A, Sparasci FM, Scotti V, Currao A, Colonna G, Ferlini M, De Luca L.   +8 more
europepmc   +1 more source